In this issue:
Side effect profiles of ICIs in cancer
Optimising treatment for LLN enlargement on MRI
Optimal treatment strategy for mCRC guided by RAS status?
Upfront FOLFIRINOX in rectal cancer & synchronous metastases
Trifluridine/tipiracil in metastatic gastric adenocarcinoma
Assess miR-31-3p expression for cetuximab in RAS wild-type mCRC?
Teenage obesity increases risk of pancreatic cancer
Assessing the risk of preterm delivery after chemotherapy
Childhood cancer survivors are at risk for VTE
Respiratory ED use among young cancer survivors
Please login below to download this issue (PDF)